George Han, MD

In this episode, ‘Redefining Treatment Success in Psoriasis,’ the expert dermatologists explore the remarkable evolution of treatment expectations in psoriasis, moving from modest improvements to ambitious goals of complete skin clearance and sustained remission. The faculty reflect that in earlier treatment paradigms even a 50% improvement in disease severity was considered a meaningful success. 

Redefining Treatment Success in Psoriasis

In this episode, ‘Redefining Treatment Success in Psoriasis,’ the expert dermatologists explorethe remarkable evolution of treatment expectations in psoriasis, moving from modest improvements to ambitious goals of complete skin clearance and sustained remission. The faculty reflect that in earlier treatment paradigms even a 50% improvement in disease severity was considered a meaningful success.

As advances in immunology and targeted biologic therapies have transformed the treatment landscape, expectations have shifted dramatically. Clinicians now have a deeper understanding of the underlying inflammatory pathways driving psoriasis, enabling the development of therapies that can deliver high levels of skin clearance with improved safety profiles. As a result, conversations with patients have evolved, with many now expecting near-complete or complete resolution of their disease.

The panelists also discussed the National Psoriasis Foundation consensus definition of on-treatment remission, representing an important step toward aligning clinical goals with patient-centered outcomes. The faculty examine the rationale for establishing a formal definition, emphasizing the importance of setting clear, achievable targets that reflect both clinical efficacy and quality of life. By incorporating perspectives from clinicians, patients, and other stakeholders, this definition underscores a broader shift in psoriasis care toward sustained disease control and meaningful remission. Overall, this discussion reinforces how far the field has progressed and sets the stage for applying these elevated expectations in clinical practice.

The next episode in this series, ‘Remission as a Goal in Psoriasis,’ features the panelists examining the clinical relevance of achieving and sustaining remission in psoriasis, emphasizing that ambitious treatment goals are increasingly attainable with modern therapies. It highlights the importance of maintaining disease control over time while aligning treatment strategies with patient quality of life and long-term outcomes.

Videos

Redefining Treatment Success in Psoriasis April 2026

Welcome back to another HCP Live Peer Exchange series. In this episode titled, ‘Evolving Treatment Expectations in Psoriasis,’ the panelists discussed how treatment goals in psoriasis have evolved alongside advances in therapeutic innovation and disease understanding. The expert faculty began by reflecting on the historical limitations of traditional therapies, including topicals, phototherapy, and early systemic agents, which were often insufficient for achieving sustained disease control. In earlier eras, treatment success was defined and accepted by improvement rather than complete clearance of the skin. 

Evolving Treatment Expectations in Psoriasis

Welcome back to another HCP Live Peer Exchange series. In this episode titled, ‘Evolving Treatment Expectations in Psoriasis,’ the panelists discussed how treatment goals in psoriasis have evolved alongside advances in therapeutic innovation and disease understanding. The expert faculty began by reflecting on the historical limitations of traditional therapies, including topicals, phototherapy, and early systemic agents, which were often insufficient for achieving sustained disease control. In earlier eras, treatment success was defined and accepted by improvement rather than complete clearance of the skin.

As the conversation progresses, the panel highlighted how the advent of biologic therapies has fundamentally reshaped expectations for both clinicians and patients. With increasing insights into psoriasis pathophysiology, particularly the role of targeted cytokine pathways, modern treatments have enabled deeper and more durable responses. This has shifted the paradigm from partial improvement to ambitious goals such as near complete or complete skin clearance.

The panelists introduce the concept of drug remission as an emerging clinical objective. The faculty discussed how advances in precision medicine have not only improved efficacy but also enhanced safety profiles, allowing clinicians to pursue sustained disease control with greater confidence. The discussion emphasized how these developments have transformed patient-provider conversations, with patients now expecting high levels of clearance without significant trade-offs in safety.

In the next episode, ‘Redefining Treatment Success in Psoriasis’, panelists will highlight how treatment expectations in psoriasis have evolved from modest improvements to achieving complete clearance and sustained remission. It will also introduce the National Psoriasis Foundation definition of on-treatment remission and its implications for aligning clinical goals with patient-centered outcomes.

George Han, MD

Articles